Morning Watchlist: Monday Edition
A quick note from Behind the Markets
Monday opens with a market that wants to feel invincible — and it just gave us the strangest piece of evidence yet.
On Friday morning, the government reported that the U.S. economy lost 23,000 jobs in July. Wall Street was expecting a gain of 83,000. Revisions erased another 103,000 jobs from May and June. And the S&P 500 finished the day higher — wrapping up its best week since April.
Read that again. The economy shed jobs for the first time in this cycle, and stocks celebrated their best week in four months.
That is not a market pricing the economy. That is a market pricing the Federal Reserve — and betting that bad news for workers is good news for rates. Maybe that bet pays. But this week brings CPI on Wednesday, PPI on Thursday, and retail sales on Friday, and every one of those releases is a chance for that logic to collide with reality.
The independent investor's edge is not predicting the first five minutes after a data print. It is knowing which businesses survive the second-order effects. Let's get to work.
1) The AI rally is broadening — but the bar is getting brutal
Friday's tape offered a useful split. Atlassian surged roughly 30% after beating on earnings and revenue with upbeat guidance. Microchip Technology jumped after forecasting revenue above estimates. Cloudflare rose after raising its full-year outlook. Twilio surged 17% on strong guidance. The strength spread to the whole neighborhood — Marvell, Micron, Palo Alto, ServiceNow all caught bids — and software's rally, in the words of the week's coverage, dispelled fears that AI would disrupt the industry rather than feed it.
But rewind a few days. Sandisk's disappointing outlook dragged the entire chip sector lower on Thursday. AMD fell hard earlier in the week despite beating estimates. The market's message is consistent: a revenue beat buys you nothing. What gets paid is durable demand, holding margins, and management that can see the next quarter clearly. Guidance is the product now.
One more Friday datapoint worth filing away: Doximity — a healthcare workflow platform — rocketed more than 70% after beating and raising. Note the sector. We will come back to why healthcare software is catching bids in the next section.
That is a better market for stock pickers. A rising tide can hide weak economics. For small and mid-cap software, networking, and specialty-chip companies, ask: Is revenue recurring? Is customer concentration falling? Does growth turn into cash, or into another round of capital spending and stock compensation?
Separate the companies collecting AI spending from the companies spending to look like AI companies. The winners will not all be household names. Some will own boring workflow, security, connectivity, or industrial exposure that customers cannot easily rip out.
Bottom line: Stop trading the AI label. Track guidance, cash conversion, and switching costs. The market is punishing impressive numbers that do not improve the business underneath — and paying almost anything for a clean guide.
2) The jobs report broke
Nonfarm payrolls fell 23,000 in July against expectations for a gain of 83,000. May and June were revised down by a combined 103,000 — meaning the labor market was weaker all spring than anyone knew. The unemployment rate fell to 4.1%, but for the worst possible reason: labor force participation dropped to 61.4%, its lowest in more than five years. People are not finding jobs; they are leaving the field. Wage growth cooled to 3.2%, the slowest since May 2021. Government shed 53,000 positions. Retail and leisure softened.
And the one sector that has been carrying this entire labor market — healthcare — grew "slower than usual," in the BLS's own framing. Even the engine is downshifting. This is precisely the "narrowing, not broadening" conclusion we reached this weekend, now stamped with an official government seal.
So what do you buy in a labor market like that? Not a staffing agency — hiring freezes are their winter. Not a payroll processor levered to headcount growth — there isn't any. You look for a business that gets paid on the labor pool that still exists, in the one sector where the workforce is still structurally growing, with revenue that does not depend on net new hiring at all.
The Stock: HealthStream (NASDAQ: HSTM)
HealthStream is the healthcare industry's largest platform for clinical workforce software — the subscription systems hospitals use to credential, schedule, train, onboard, and retain nurses and physicians. Here is why it fits this exact moment: hospitals pay HealthStream per professional under management, on multi-year subscriptions. As long as America employs millions of healthcare workers — and healthcare remains the only sector adding jobs at all — HealthStream collects. It does not need a hiring boom. It monetizes churn, compliance, and credentialing intensity, which if anything go up when the labor market gets tight and hospitals fight to retain staff.
The business just proved it. A week ago, HealthStream reported record quarterly revenue of $83.7 million, up 12.5%, with record adjusted EBITDA of $20.6 million and EPS of $0.23 that beat the $0.17 consensus by 35%. Subscription revenue grew 11.2% even before acquisitions. Management raised full-year revenue guidance to $327–332 million. The print is public — you are not buying into an earnings date.
This is the right business at a demanding price. The stock sits around $29, near the top of its 52-week range of $19.50 to $30, and analyst coverage is thin — the published targets cluster around $31, barely above where it trades. The quarter had help: a $2.0 million one-time revenue catch-up from an old contract and $3.1 million from acquisitions, so underlying organic growth is closer to 8%. Legacy credentialing and scheduling revenue fell 15% as customers migrate to newer products. Management trimmed net-income guidance even while raising revenue guidance, because it is spending harder on growth. And the trailing multiple is rich — north of 40 times earnings for a single-digit organic grower.
This is the name for the thesis, and the thesis is not going anywhere — healthcare workforce complexity compounds regardless of what the Fed does. Put it on the watchlist at the top of the page. A market that just repriced the entire labor complex will hand you better entries in a $29 stock with a $31 target. The business earned its spot. Let the price earn yours.
Bottom line: The labor market is narrowing to a single engine, and even that engine is slowing. Own the toll collector on the healthcare workforce — on your price, not the market's.
3) China's export machine is humming. Read the fine print before you celebrate — or panic.
China's July trade data landed Friday, and it beat again: exports grew 23.9% in dollar terms against forecasts of 22.2%, easing from June's blistering 27% but still running at a pace the pre-2026 world would have called impossible. The engine is exactly what you would guess: a worldwide AI infrastructure buildout. Semiconductor exports nearly doubled from a year ago. High-tech product exports soared 40.7%, and in July high-tech goods drove nearly 60% of the entire month's export increase.
But two details complicate the draft narrative that exports are doing all the work.
First, imports grew even faster — up 27.5%, only slightly below forecasts. Some of that is AI-hardware inputs and commodities rather than a household spending revival, and mechanical and electrical product imports jumped nearly 30%. So the domestic economy is not simply comatose; it is importing what its export machine needs. The distinction still matters — a factory restocking is not a consumer recovering — but "exports strong, home front frozen" is too simple.
Second, the trade friction the draft predicted has already started. In late July, the U.S. applied a new 12.5% levy on Chinese products, replacing a lapsed temporary 10% one. Shipments to the U.S. still grew about 17% — partly a rush to beat further tariff escalation, which borrows from future quarters. And Washington's Friday move on polysilicon (see the final section) shows exactly how this pressure valve gets answered: with floors, tariffs, and industrial policy.
The investing read stands, sharpened: export-linked electronics, industrial automation, logistics, and select materials benefit from goods that are actually moving. Consumer-facing China plays and property-sensitive lenders still need proof that never seems to arrive. And any U.S.-listed company whose margin depends on cheap Chinese intermediate goods now carries policy risk that can materialize on a random Friday.
Bottom line: China's export growth is real, and it is increasingly an AI-hardware story. Follow the goods that move and the suppliers that get paid — and price in the tariffs that are no longer hypothetical.
4) CPI and PPI are not Fed trivia. This week, they are the whole ballgame.
The calendar: CPI and Real Earnings on Wednesday, PPI on Thursday, retail sales and the preliminary Michigan consumer survey on Friday.
Here is why this particular CPI print matters more than most. Go back nine days: the Fed held rates steady with three officials dissenting in favor of a hike, and in the days that followed, several Fed officials publicly argued for raising rates as soon as September if inflation did not cool. Then Friday's jobs report showed the economy losing jobs, wage growth at a five-year low, and workers leaving the labor force — and traders immediately repriced their Fed bets.
So the two halves of the Fed's mandate are now pointing in opposite directions. Inflation says hike. Employment says the opposite. Wednesday's CPI is the tiebreaker, and every asset that rallied on Friday's "bad news is good news" logic is implicitly betting the tiebreaker goes the dovish way. If consumer prices stay sticky — or if Thursday's PPI shows producer prices reaccelerating into a weakening labor market — the invincible market meets the one combination it has no playbook for: stagflation-lite.
Which brings this back to what you should actually care about: the handoff from prices to profits. If input costs reaccelerate while the consumer weakens, the question on every earnings call becomes whether companies can pass costs through without losing volume. That pressure lands hardest on smaller businesses with thin margins, floating-rate debt, and weak bargaining power — the exact cohort that also cannot hire its way out of trouble anymore.
The better question for every company you own: are margins holding because of productivity, or because management is delaying investment and cutting easy costs? Friday's retail sales will show whether customers absorb price increases or trade down — and we already know from Albertsons' own CEO which direction the trade-down is flowing.
Bottom line: This week's data is a test of pricing power with the Fed's next move riding on it. Favor companies that can raise prices, protect unit demand, and fund growth internally. Avoid businesses that need perfect macro weather — because whatever Wednesday brings, the weather will not be perfect for everyone.
5) Washington just put a floor under solar materials. The biggest winner doesn't even use the stuff.
On Friday, the White House imposed a series of minimum import prices and a 15% tariff on products made from polysilicon — the raw material at the base of most solar panels and semiconductors, produced overwhelmingly in China. The measures are designed to protect U.S. polysilicon and downstream solar manufacturing, with a broader Section 232 investigation still pending.
Solar stocks may celebrate. That is not the whole trade. A policy floor helps domestic producers, but it raises the cost curve for every panel maker, developer, and installer who assumed cheap imported inputs would last forever. Somebody pays the floor, and it is usually the buyer.
Which is why the most interesting angle is the company that opted out of this fight entirely.
The Stock: First Solar (NASDAQ: FSLR)
Here is the detail most coverage of the polysilicon news skipped: First Solar — America's largest solar manufacturer — does not use polysilicon at all. Its thin-film modules are built on cadmium telluride semiconductor technology, an entirely different chemistry. So Friday's action raises input costs for its crystalline-silicon competitors, most of whom depend on the very Chinese supply chain being tariffed, while First Solar's U.S.-built product is untouched. The company understood this instantly: it publicly voiced strong support for the administration's action within hours.
And this policy tailwind lands on a business that just posted the best margins in its history. Second-quarter results, reported July 30: net income of $423 million, or $3.92 per diluted share — beating the $2.83 consensus by 38% — with gross margin expanding to roughly 57%. The company crossed 100 gigawatts of cumulative module sales, holds a contracted backlog of 45.1 gigawatts stretching through 2030 — years of volume and pricing visibility — carries a $1.7 billion net cash position, and trades at roughly 14 times trailing earnings with a forward multiple under 13. For a company with hyperscaler demand behind it, that is not an AI-bubble multiple. Analysts rate it a Buy on average.
Now the two-sided part, and there is real weight on the other side. First, the stock trades almost exactly at the analyst consensus target (~$252–255), and the spread underneath is wide — Wells Fargo at $300 Overweight, Guggenheim $282 Buy, but Jefferies down at $196 with a Hold. The market has partially caught on. Second, a securities class action was filed this summer alleging misrepresentations around Series 6 module production underutilization and the costs of onshoring to South Carolina; an investigation announcement is not a finding, but it is a live overhang you should know exists. Third, the same trade-policy machine cutting rivals' legs can nick First Solar too: its Southeast Asian plants are running roughly $30 million per quarter of underutilization costs while Section 232 stays unresolved, guidance already absorbs a $60–80 million net tariff impact, and revenue actually fell 4% year over year last quarter on contract terminations. Policy giveth, policy taketh.
So the frame is the same one we used all weekend: the right company, priced like the market already read the memo. On the watchlist — with the note that unlike most policy trades, this one's advantage is structural chemistry, not a subsidy that can be repealed.
Bottom line: A protected supply chain is not automatically a profitable supply chain — but a company that never needed the protected input is playing a different game. Follow who owns capacity, who bears the input cost, and who can earn returns without another Washington announcement.
Before You Go
The market is near records because investors believe the good news will keep arriving. Friday tested that belief in the strangest way possible: the good news was the bad news. The economy lost jobs, and stocks had their best week since April, because the market has decided it trades the Fed, not the economy.
Here is the contrarian question for Monday, sharpened by the week behind us: if the economy is as strong as Wall Street says, why did it just lose 23,000 jobs — and if it is as weak as the payrolls say, why is anyone confident about the earnings guidance being handed out like candy?
Both of those can't be true. Wednesday's CPI starts sorting out which one is. Between now and then, own businesses that don't need the answer to go their way.
Found this helpful? Share it with others.
Written by Behind the Markets